Skip to content
AnalystLens

METLIFE INC 8-K Report, Financial Results (Apr 30, 2025)

Reports
Earnings & Results·Regulation FD·Other Events+1
Filing Date
Filed April 30, 2025
Period End
April 30, 2025
In the record · 2016–202610-K1110-Q328-K249

MET filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 249 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Jun ’22Jun ’22
  3. Leadership change8-K · Feb ’26Feb ’26

01—Abstract

Summary

Summary of the 8-K filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.

MetLife reported first-quarter 2025 results that were mixed on the headline but solid on the underlying business.

GAAP net income rose 10% to $879 milliona ($1.28 per share, up 16%), helped mainly by a swing to net derivative gains of $432 million from net derivative losses a year earlier. Adjusted earnings, the measure management uses to evaluate segment performance, rose only 1% to $1.35 billion, or $1.96 per diluted share (up 7%). Adjusted earnings were held back by unfavorable foreign currency effects, lower recurring interest margins, and weaker Asia results, partly offset by Group Benefits (up 29%) and higher variable investment income (up 26% to $327 million).

Premiums, fees and other revenues rose 14% to $13.6 billionb, but excluding pension risk transfers (PRT) growth was only 1%. Balance sheet and capital indicators were stable. Book value per share rose 2% to $35.16 and adjusted book value per share rose 4% to $55.01.

MetLife returned $1.8 billionc to shareholders in the quarter through buybacks and dividends, and the Board approved a new $3.0 billion repurchase authorization. Holding company cash and liquid assets were $4.5 billion, and the 2024 combined U.S. RBC ratio was 388%, above the 360% target. Strategically, MetLife agreed in April to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves to a subsidiary of Talcott Financial Group, a transaction expected to close in the second half of 2025 subject to regulatory approval.

Management estimates the deal's total expected value at about $250 milliond, with foregone adjusted earnings of roughly $100 million a year partly offset by hedge cost savings of about $45 million a year. The company also cited a 2025 variable investment income target of about $1.7 billion pre-tax.

02—Key points

Key Highlights

  1. GAAP net income increased 10% to $879 million, or $1.28 per diluted share (up 16%), primarily due to a $432 million net derivative gain versus a $979 million loss a year earlier.
  2. Adjusted earnings rose 1% to $1.35 billion ($1.96 per share, up 7%); constant-currency adjusted earnings rose 5%, and there were no notable items in the quarter.
  3. Group Benefits adjusted earnings rose 29% to $367 million on favorable life underwriting from lower working-age mortality, while Asia adjusted earnings fell 12% to $374 million.
  4. Premiums, fees and other revenues rose 14% to $13.6 billion, but excluding PRT the increase was only 1% to $12.1 billion.
  5. Variable investment income increased 26% to $327 million, driven by real estate and other fund returns; management's full-year 2025 guidance is about $1.7 billion pre-tax.
  6. Book value per share rose 2% to $35.16 and adjusted book value per share rose 4% to $55.01; the direct expense ratio improved to 10.7% from 11.9%.
  7. Authorized a new $3.0 billion share repurchase program and returned $1.8 billion to shareholders in the quarter; holding company cash was $4.5 billion.

03—Questions

Frequently Asked Questions

  1. Why did net income rise 10% while adjusted earnings rose only 1%?

    GAAP net income includes net derivative gains and losses and market risk benefit remeasurements, which are excluded from adjusted earnings. In Q1 2025 MetLife booked a $432 million net derivative gain (compared with a $979 million loss in Q1 2024), which lifted GAAP results. Adjusted earnings strip out this volatility and showed only modest growth, held back by currency, lower recurring interest margins, and weaker Asia results.

  2. What is the Talcott variable annuity transaction, and how does it affect earnings?

    MetLife agreed in April 2025 to transfer about $10 billion of U.S. retail variable annuity and rider reserves to a subsidiary of Talcott Financial Group via funds withheld and modified coinsurance. Customer service stays with MetLife, and MIM will manage about $6 billion of assets. Management expects a total value of about $250 million, with roughly $100 million of foregone annual adjusted earnings partly offset by about $45 million of annual hedge cost savings. The deal is expected to close in the second half of 2025, subject to regulatory approval.

  3. How much capital is MetLife returning, and how much room does it have for buybacks?

    MetLife returned $1.8 billion to shareholders in Q1 2025 through share repurchases and common dividends, with roughly $1.4 billion in buybacks in the quarter and about $150 million more in April. The Board approved a new $3.0 billion repurchase authorization. Holding company cash and liquid assets were $4.5 billion against a stated $3.0 to $4.0 billion cash buffer, and the 2024 combined U.S. RBC ratio was 388%, above the 360% target.

  4. Is the growth in premiums and fees sustainable?

    The headline 14% increase in premiums, fees and other revenues is largely attributable to pension risk transfer (PRT) deals in RIS. Excluding PRT, adjusted premiums, fees and other revenues grew only about 1%, to $12.1 billion. Investors should therefore treat the PRT contribution as lumpy and not indicative of underlying premium growth, which remained modest.

04—Continue

← View all 8-K filings